There are substantial costs associated with
the late discovery of the MRSA (or Methicillin-resistant Staphylococcus aureus)
super-bug and other hospital-acquired infections. In the US alone, there are
the challenges posed to patients and healthcare providers, including tens of
thousands of invasive infections and deaths and billions in treatments costs.
Spanish-company Zenosense strongly believes
it has identified a lucrative new market segment as there is no existing,
cost-effective system to serve as a “smoke alarm” for MRSA/SA with the purpose
of detecting infection early in patients or the rooms of a healthcare building.
To answer this largely unmet need, Zenosense has entered into an exclusive
global license agreement with Sgenia Group to develop an effective detector for
MRSA/SA, and Sgenia has established a new, dedicated subsidiary for the
project: Zenon Biosystem.
Zenon is contracted, on a phased basis, to
produce this sophisticated device, which will be based on an algal/water sensor
platform that already exists. At this point, the plan is to use a single,
commercial “off-the-shelf” gas sensor to sample the air and continuously
monitor for the airborne volatile organic compounds (VOCs) signature emitted by
MRSA/SA. The MRSA/SA VOC signature is only emitted when the bacteria has
infected and presented itself as a disease in the patient. It can be detected
prior to the patient being obviously symptomatic, enabling an earlier
intervention.
Zenosense has made progress since the
development of its MRSA device began in December of 2013. As of May 2014, it
extended its development and exclusive license agreement with Sgenia to include
cancer sensory devices. Under the terms of the extension, Zenosense has the
option of funding the development of prospective cancer sensory devices that
may be based on the Sgenia technology. Assuming it finances the project,
Zenosense will have the right to manufacture, market, and sell any resulting
devices that are developed.
Zenosense believes the sensory technology and
algorithmic processing in development for MRSA detection could, if successful,
be applied to certain cancer sensory devices. Some cancers, such as lung and
colon, produce volatile organic compounds in an individual’s breath in a
similar way that MRSA does. If the cancer-specific pattern of VOCs can be
identified, Zenosense believes that a fairly-straightforward alteration of a
successful MRSA detection technology may enable it to create a similar device
for the exposure of certain cancers.
As with the MRSA/SA detector it has under
development, Zenosense believes there could be huge demand for a relatively
minimal-cost, rapid-detection device for these types of cancer. Such a device
could allow for much wider screening and the ability to detect, for example, lung
cancer at a much earlier stage and on a mass scale. Presently, lung cancer is
usually detected at a late stage when fewer than 25% of cases can be cured;
however, if detected in Stage I, there is a 70% cure rate.
For more information, visit www.zenosense.net
About
QualityStocks
QualityStocks is committed to connecting
subscribers with companies that have huge potential to succeed in the short and
long-term future. We offer several ways for investors to find, evaluate, and
learn more about investing in these companies.
Sign up for “The QualityStocks Daily
Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks
website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment